Unlocking the Potential of CES1P1: A drug Target and Biomarker

Target Name: CES1P1

NCBI ID: G51716

CES1P1

Unlocking the Potential of CES1P1: A drug Target and Biomarker

Introduction

Cysteinyl Esterase (CES) is a family of transmembrane proteins that play a crucial role in various physiological processes. The CES family includes CES1 to CES4, of which CES1P1 is a glycosylated modified CES that has been found to be associated with a variety of diseases, including Nervous system, liver, kidneys, connective tissue and tumors. Aberrant expression of CES1P1 is associated with various diseases, such as neurodegenerative diseases, liver diseases, kidney diseases and tumor development. Therefore, studying the role of CES1P1 in disease is of great significance for revealing the pathogenesis of the disease and developing new treatments.

Pharmacological significance of CES1P1

As a new target, CES1P1 has good pharmacological significance. CES1P1 expression is up-regulated in a variety of diseases and is associated with an increased risk of multiple diseases. By targeting CES1P1, disease risk can be reduced, thereby providing new means for treating and preventing disease.

Disease association studies of CES1P1

CES1P1 is associated with a variety of diseases, including the nervous system, liver, kidney, connective tissue, and tumors. Studies have found that the expression level of CES1P1 is associated with an increased risk of various diseases. For example, upregulation of CES1P1 expression is associated with an increased incidence of Parkinson's disease, downregulation of CES1P1 expression is associated with an increased incidence of neurodegenerative diseases such as Alzheimer's disease, and upregulation of CES1P1 expression is associated with an increased incidence of liver diseases such as cirrhosis. Down-regulation of CES1P1 expression is associated with an increased incidence of kidney diseases such as glomerulonephritis, up-regulation of CES1P1 expression is associated with an increased incidence of connective tissue diseases such as rheumatoid arthritis, and down-regulation of CES1P1 expression is associated with an increased incidence of tumors.

Study on the biological functions of CES1P1

Research on the biological functions of CES1P1 in various diseases has also received widespread attention. Studies have shown that CES1P1 is involved in the formation of neuronal synapses, the release of neurotransmitters and the maintenance of neuronal connections in the nervous system. In the liver, CES1P1 is involved in liver cell proliferation, apoptosis, and regeneration. In the kidney, CES1P1 is involved in glomerular filtration and tubular reabsorption. In connective tissue, CES1P1 is involved in the occurrence of inflammatory responses and fibrosis. In tumors, CES1P1 is involved in the growth, invasion and metastasis of tumor cells.

Drug development for CES1P1

As a new target, CES1P1 has good prospects for drug development. Currently, a variety of drugs that inhibit CES1P1 expression have entered clinical research, including anti-CES1P1 antibodies, Cesmainide, NEDD8 and Galectin-3, etc. These drugs can reduce the expression level of CES1P1 through different mechanisms of action, thereby inhibiting the role of CES1P1 in the disease. These drugs have broad application prospects in the treatment of various diseases and provide new means for the treatment of diseases.

Biomarker research on CES1P1

CES1P1 also has broad application prospects in biomarker research in disease diagnosis and treatment. By detecting the expression level of CES1P1, early diagnosis of the disease and monitoring of disease progression can be achieved. Detection methods for CES1P1 expression levels include enzyme-linked immunosorbent assay, immunofluorescence staining, and gene sequencing. These methods have high sensitivity and specificity and can accurately detect CES1P1 expression levels.

Potential role of CES1P1 in disease treatment

The potential role of CES1P1 in disease treatment has also received widespread attention. By targeting CES1P1, disease risk can be reduced, thereby providing new means for treating and preventing disease. Currently, a variety of drugs that inhibit CES1P1 expression have entered clinical research, including anti-CES1P1 antibodies, Cesmainide, NEDD8 and Galectin-3, etc. These drugs can reduce the expression level of CES1P1 through different mechanisms of action, thereby inhibiting the role of CES1P1 in the disease. These drugs are treating

Protein Name: Carboxylesterase 1 Pseudogene 1

Functions: Has no esterase activity

The "CES1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CES1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets